- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- HEXONE PHARM
HEXONE PHARM Share Price 
(HXPH)
Here is the latest stock price and chart of HEXONE PHARM.
| Live BSE Quotes |
|---|
| Not listed |
| Live NSE Quotes |
|---|
| Not listed |
| BSE Sensex | CNX Nifty |
|
| |
Today's Market
Sensex Opens Flat; Realty & Bank Stocks Lose(09:30 am)
Asian stock markets opened in red today after a new round of US-China trade tariffs kicked in. Meanwhile, the S&P 500 and the Dow closed lower on Monday as market participants awaited.
Related Views On News
Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)
Mar 14, 2018Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?
Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)
Mar 12, 2018Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?
Apollo Micro Systems Ltd. (IPO)
Jan 9, 2018Should you subscribe to the IPO of Apollo Micro Systems Ltd?
Khadim India Ltd. (IPO)
Oct 31, 2017Should you subscribe to the IPO of Khadim India Ltd?
Mahindra Logistics Ltd. (IPO)
Oct 28, 2017Should you subscribe to the IPO of Mahindra Logistics Ltd?
More Views on NewsMost Popular
My First Pharma Stock Recommendation!(The 5 Minute Wrapup)
Sep 21, 2018This company has not only created a niche in the pharma space, it has done so profitably.
Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)
Sep 12, 2018Richa has discovered the single most profitable opportunity in the market - read on to discover more...
Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)
Sep 12, 2018PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.
Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)
Sep 14, 2018Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.
How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)
Sep 17, 2018PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.
MoreTRACK HEXONE PHARM
- Track your investment in HEXONE PHARM with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.